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Impact of proton pump inhibitor treatment on gastrointestinal 
bleeding associated with non-steroidal anti-inflammatory 
drug use among post-myocardial infarction patients taking 
antithrombotics: nationwide study
Anne-Marie Schjerning Olsen,1,2 Jesper Lindhardsen,1 Gunnar H Gislason,1,3,4 Patricia McGettigan,2 
Mark A Hlatky,5 Emil Fosbøl,6 Lars Køber,6 Christian Torp-Pedersen,7 Morten Lamberts8 
ABSTRACT
Study queStion
What is the effect of proton pump inhibitors (PPIs) on 
the risk of gastrointestinal bleeding in post-myocardial 
infarction patients taking antithrombotics and treated 
with non-steroidal anti-inflammatory drugs (NSAIDs)?
MethodS
This was a nationwide cohort study based on linked 
administrative registry data from all hospitals in 
Denmark between 1997 and 2011. The study included 
patients aged 30 years and over admitted with a first 
myocardial infarction who survived at least 30 days 
after discharge. The association between PPIs and risk 
of gastrointestinal bleeding according to NSAID plus 
antithrombotic therapy was estimated using adjusted 
time dependent Cox regression models.
Study anSwer and liMitationS
The use of PPIs was independently associated with 
decreased risk of gastrointestinal bleeding in post-
myocardial infarction patients taking antithrombotics 
and treated with NSAIDs. Of 82 955 post-myocardial 
infarction patients (mean age 67.4 years, 64% 
(n=53 070) men), all of whom were taking single or 
dual antithrombotic therapy, 42.5% (n=35 233) filled at 
least one prescription for NSAIDs and 45.5% (n=37 771) 
received PPIs. Over a mean follow-up of 5.1 years, 3229 
gastrointestinal bleeds occurred. The crude incidence 
rates of bleeding (events/100 person years) on NSAID 
plus antithrombotic therapy were 1.8 for patients 
taking PPIs and 2.1 for those not taking PPIs. 
The adjusted risk of bleeding was lower with PPI use 
(hazard ratio 0.72, 95% confidence interval 0.54 to 
0.95) regardless of antithrombotic treatment regimen, 
type of NSAID, and type of PPI used. The main 
limitation of the study is its observational non-
randomised design. The results suggest that PPI 
treatment probably has a beneficial effect regardless 
of underlying gastrointestinal risk and that when 
NSAIDs cannot be avoided in post-myocardial 
infarction patients, physicians might prescribe a PPI as 
well. The study does not clarify whether PPIs might be 
safely omitted in specific subgroups of patients with a 
low risk of gastrointestinal bleeding.
what thiS Study addS
In post-myocardial infarction patients, bleeding 
complications have been associated with both 
antithrombotic and NSAID treatment. Concurrent use 
of PPIs was independently associated with a 
decreased risk of gastrointestinal bleeding in post-
myocardial infarction patients taking antithrombotics 
and NSAID, regardless of antithrombotic treatment 
regimen, type of NSAID, and type of PPI used.
Funding, CoMpeting intereStS, data Sharing
AMSO has received a grant from the Danish Council 
of Independent Research (grant 12-132760). GHG is 
supported by an unrestricted research scholarship 
from the Novo Nordisk Foundation.
Introduction
Antithrombotic treatments are widely used in post- 
myocardial infarction patients to reduce thromboem-
bolic risk, but at the cost of increased risk of bleeding.1 2 
Gastrointestinal haemorrhage is the most common seri-
ous bleeding complication associated with antithrom-
botic treatment.1 Non-steroidal anti-inflammatory drugs 
(NSAIDs) are effective and widely used analgesics. 
Much attention has been given to their gastrointestinal 
safety.3-7 They have been shown to carry a substantial 
independent risk of bleeding in cardiovascular patients 
when co-prescribed with antithrombotics, even with 
short term use (<14 days).8-10 Randomised controlled tri-
als have reported that proton pump inhibitors (PPIs) 
reduce rates of recurrent gastrointestinal bleeding in 
patients receiving antithrombotics.11 12 Although NSAIDs 
are discouraged in post-myocardial infarction patients, 
pain is a common condition and, in practice, they are 
frequently prescribed.13 14 American specialist cardiol-
ogy and gastroenterology guidelines recommend that 
WhAT IS AlReAdy knoWn on ThIS TopIC
Although administration of non-steroidal anti-inflammatory drugs (NSAIDs) to 
post-myocardial infarction patients is discouraged owing to their cardiovascular 
risks, NSAIDs are still widely used because painful conditions are common
Among post-myocardial infarction patients, bleeding complications have been 
associated with both antithrombotic and NSAID treatment
The effect of proton pump inhibitors (PPIs) on the risk of gastrointestinal bleeding 
in post-myocardial infarction patients taking antithrombotics who are treated with 
NSAIDs is unknown
WhAT ThIS STudy AddS
Concurrent use of PPIs was independently associated with decreased risk of 
gastrointestinal bleeding in post-myocardial infarction patients taking 
antithrombotics who were treated with NSAIDs
This finding was independent of antithrombotic treatment regimen, type of NSAID, 
and type of PPI used
Post-myocardial infarction patients in whom NSAIDs are judged necessary might 
benefit from PPI treatment as well
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PPIs should be used with both antithrombotic and 
NSAID treatments in patients judged to be at high risk 
of gastrointestinal bleeding.15  In the United Kingdom, 
the National Institute for Health and Care Excellence 
(NICE) recommends routine PPI co-prescription with 
NSAIDs for everyone aged 45 years and older with 
osteoarthritis, rheumatoid arthritis, or chronic low 
back pain,16  as well as for people taking antithrombot-
ics who are at high risk of gastrointestinal adverse 
effects including bleeding.17 However, the potential 
benefit of PPI therapy used with antithrombotic/
NSAID combinations in post-myocardial infarction 
patients irrespective of gastrointestinal risk is un-
known. We therefore investigated the effect of PPIs on 
the risk of bleeding in Danish post-myocardial infarc-
tion patients taking antithrombotics who were also 
treated with NSAIDs.
Methods
data sources
Diagnostic data came from the Danish National Patient 
Registry, which using ICD-10 (international classifica-
tion of diseases, 10th revision) to classify hospital 
admissions (supplementary table 1).18  Each hospital 
admission is registered with one main discharge diag-
nosis and one or more supplementary diagnoses if 
appropriate. Information on vital status (dead or alive) 
came from the civil registration system through Statis-
tics Denmark. We obtained primary, secondary, and 
contributing causes of death recorded by a physician 
from the National Causes of Death Registry. The 
National Prescription Registry provided information on 
the date of dispensing, quantity dispensed, strength, 
and formulation of all drugs dispensed from Danish 
pharmacies and classified according to the Anatomical 
Therapeutic Chemical (ATC) system (supplementary 
table 2). The partial reimbursement of drug expenses by 
the Danish healthcare system requires all pharmacies 
to register each drug dispensed in the National Pre-
scription Registry, ensuring complete registration.19 
In Denmark, every resident has a permanent unique 
civil registration number that enables linkage across 
administrative registries.
Study population and follow-up
We identified all patients aged 30 years and over in the 
National Patient Registry between 1997 and 2011 who 
had a primary diagnosis of acute myocardial infarction 
(ICD-10 code I21 to I22), received antithrombotics, and 
survived at least 30 days from discharge (date of inclu-
sion). The 30 day restriction defined a quarantine 
period. The follow-up period started after the 30 day 
quarantine period to minimise risk of immortal time 
bias. To avoid selection bias, we used a new user design, 
excluding patients who collected a prescription for an 
NSAID during the quarantine period (n=5711). Patients 
were followed until one of the following events (which-
ever came first): event of interest, emigration, death, or 
end of study period (31 December 2011). The diagnosis 
of myocardial infarction has been validated with a 
 specificity exceeding 90%.20
antithrombotic, ppi, and nSaid treatment
We used claimed prescriptions of aspirin or clopidogrel 
to characterise patients as receiving either antithrom-
botic monotherapy (aspirin or clopidogrel) or dual ther-
apy. We excluded post-myocardial infarction patients 
who received no antithrombotic (n=15 353) or an oral 
anticoagulant only (n=1440). We identified all claimed 
prescriptions for NSAIDs (ATC M01A, excluding glucos-
amine (M01AX05)). We categorised rofecoxib and cele-
coxib as cyclo-oxygenase-2 selective (COX 2) inhibitors; 
ibuprofen, diclofenac, and naproxen as non-selective 
NSAIDs; and all other NSAIDs as “other” NSAIDs. The 
only NSAID available in Denmark without prescription 
is ibuprofen (since 2001). We categorised PPI treatment 
in one group (ATC A02BC); we also examined five indi-
vidual PPIs—omeprazole, lansoprazole, pantoprazole, 
esmoprazole, and rabeprazole.
We calculated exposure periods for NSAIDs and PPIs 
for each patient by estimating a daily dose after com-
paring the accumulated dose and the elapsed time from 
consecutive prescriptions for the drug under investiga-
tion. We determined ongoing exposure by dividing the 
number of tablets/capsules dispensed by the estimated 
average dosage. If only one prescription was registered 
for an individual, we used a standard dosage, defined 
as the minimal recommended dosage, to estimate the 
daily dose. We used information on increasing or 
decreasing dosage only to continuously assess whether 
tablets were available. We defined exposure as having 
occurred when patients had drug available and discon-
tinuation as when they had no more drug available. 
Methods for determining dose and treatment duration 
have been described previously.21 22  For most patients, 
treatment regimens changed during the study period, 
so we treated NSAID and PPI use in the analysis as time 
varying exposures—that is, patients changed exposure 
group according to claimed prescriptions. Each 
patient’s exposure group at inclusion defined baseline 
treatment, shown in the table with the covariante distri-
butions (supplementary figure).
Comorbidity
We identified comorbidities from previous diagnoses 
and at discharge from the index myocardial infarction, 
as specified in the Ontario acute myocardial infarction 
mortality prediction rule, and potential risk factors for 
bleeding (previous bleeding, alcohol consumption, 
liver disease, and ulcers).23  The Ontario acute myocar-
dial infarction mortality prediction rule is a logistic 
regression model that predicts 30 day and one year 
mortality by using 11 variables determinable from hos-
pital discharge databases (age, sex, shock, diabetes 
with complications, congestive heart failure, cancer, 
cerebrovascular disease, pulmonary oedema, acute 
renal failure, chronic renal failure, cardiac dysrhyth-
mia). In our analyses, we incorporated each variable as 
a covariate and permitted diagnoses up to one year pre-
viously (supplementary table 1).24 To account for accu-
mulation of risk factors during follow-up, we did an 
analysis including all variables in the main analysis 
as  time dependent (exempt for inclusion year and 
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 percutaneous coronary intervention status (considered 
as related to myocardial infarction inclusion criteria) 
and previous peptic ulcer disease (considered an inter-
mediate variable of the primary outcome during fol-
low-up)). During the entire span of the database, 
patients could change status on the date of exposure.
outcome
We defined the primary outcome of gastrointestinal 
bleeding as hospital admission for or death from a 
bleeding gastrointestinal ulcer, haematemesis, melena, 
or unspecified gastrointestinal bleeding from the 
National Causes of Death Register and National Patient 
Register.25 Occurrence and type of bleeding as recorded 
in hospital databases have shown a positive predictive 
value of 89-99%.
Statistical methods
We calculated crude incidence rates as number of events 
per 100 person years according to the different treatment 
regimens. We estimated the effects of PPI treatment on 
gastrointestinal bleeding with adjusted Cox proportional 
hazards models in terms of hazard ratios and 95% confi-
dence intervals for gastrointestinal bleeding with the 
drug exposure continuously updating—that is, as time 
varying exposure allocated according to treatment regi-
men. We considered patients to be at risk only when 
exposed to the drug (during active treatment). Each 
patient could have multiple treatment groups through-
out follow-up. We calculated risk time (person years) 
only for the active treatment period. The timescale in the 
Cox model was days passed since inclusion. We adjusted 
all models for age, sex, year of index hospital admission, 
concomitant drugs, comorbidity, and percutaneous cor-
onary intervention status. We did additional analyses to 
assess any association between PPI use and individual 
antithrombotic regimens and NSAIDs.
We did nine sensitivity analyses. (1) To take account 
of any effect of over the counter NSAID use, we ended 
follow-up at 2001. (2) To take account of dabigatran or 
ticagrelor use (released in Denmark, August 2011), we 
ended follow-up in December 2010. (3) We examined 
cardiovascular death as a solo endpoint. (4) We strati-
fied the cohort at 65 years to take account of guidelines 
recommending PPIs for people over 65 taking 
 antithrombotic treatment. (5) We controlled for the vari-
ables included in the HAS-BLED score. (6) We did an 
analysis including all covariates as time dependent. (7) 
We stratified the population in two groups: high (previ-
ous bleeding) and low (no previous bleeding) risk of 
gastrointestinal bleeding. (8) Although the indication 
for NSAID use was not systematically available, we were 
able to do an analysis of patients with rheumatoid 
arthritis. (9) We examined the effect of duration of 
NSAID treatment (0-14 days and >14 days).
We confirmed the validity of the proportional hazard 
assumption, linearity of continuous variables, and 
lack of interaction and chose a significance level of 
0.05. We used SAS 9.2 and Stata 11.0 for all statistical 
calculations.
patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures; nor were they involved in 
the design and implementation of the study. There are 
no plans to involve patients in dissemination.
Results
A total of 128 751 patients were admitted with a first myo-
cardial infarction in the period 1997 to 2011, of whom 
82 955 (64.4%) were taking single or dual antithrombotic 
therapy and met the study inclusion criteria (fig 1 ). Base-
line characteristics included 67.4 years mean age, 64% 
male, and 6.6% with a history of previous gastrointesti-
nal bleeding (table ). A total of 35 233 (42.5%) patients had 
one or more NSAID prescription claim after discharge; 
37 711 (45.5%) received a PPI, and 10 613 (12.8%) had con-
current NSAID and PPI exposure (fig 2 ). The proportions 
receiving a PPI in the year after their first myocardial 
infarction increased from 15% in 1997 to 37% by 2010. 
The proportions receiving NSAIDs peaked at 20% in 2002 
and subsequently declined, whereas the proportions 
receiving a PPI concurrently with an NSAID increased 
from less than 10% to more than 30% by 2010 (fig 2).
gastrointestinal bleeding
We identified 3229 gastrointestinal bleeding events, 282 
(8.7%) of which were fatal. A total of 327 events were 
registered during NSAID treatment. The overall crude 
incidence rate was 0.8  (95% confidence interval 0.7 to 
0.8) events per 100 person years The crude incidence 
rate of gastrointestinal bleeding on NSAID treatment 
was 2.1 (1.8 to 2.4) events per 100 person years without 
concurrent PPI treatment and 1.8 (1.4 to 2.4) with con-
current PPI treatment (fig 3 ). After multivariable adjust-
ment for baseline differences, use of PPIs concurrently 
with combined antithrombotic and NSAID treatment 
was associated with a significantly lower risk of gastro-
intestinal bleeding (hazard ratio 0.72, 95% confidence 
interval 0.54 to 0.95) compared with treatment without 
concurrent PPIs (fig 3). Compared with combined anti-
thrombotic and NSAID treatment (without concurrent 
First time myocardial infarction patients >30 years old
between 1 January and 31 December 2011 (n=128 751)
First time myocardial infarction included >30 years on antithrombotic
treatment (45.3% dual therapy and 54.7% monotherapy) (n=82 955)
PPI and
NSAID (n=571)
PPI (n=12 334)NSAID (n=2006)No PPI and no
NSAID (n=68 044)
Excluded (n=45 796):
  Bleeding during 30 days aer discharge from hospital (n=774)
  Death from other causes during 30 days aer discharge from hospital (n=22 518)
  NSAID during 30 days aer discharge from hospital (n=5711)
  No antithrombotic treatment (n=15 353)
  Vitamin K antagonist (n=1440)
Fig 1 | Flow chart of study population. quarantine period=30 days after discharge from 
hospital. Cohort consisted of patients who were alive after quarantine period and who 
were taking single or dual antithrombotic treatment. Cohort was further divided into four 
groups according to non-steroidal anti-inflammatory drug (nSaid) and proton pump 
inhibitors (ppi) use
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PPI), taking antithrombotics only (without NSAID or 
PPI) or antithrombotics with concurrent PPI treatment 
(without NSAID) were each associated with a lower risk 
of gastrointestinal bleeding. The bleeding risk associ-
ated with concurrent PPI and NSAID treatment was sim-
ilar for each antithrombotic regimen (supplementary 
table 3). PPIs taken  concurrently with NSAID and dual 
antithrombotic therapy were associated with a reduced 
risk of gastrointestinal bleeding (incidence rate 2.5 
(1.3 to 4.8) events per 100 person years) compared with 
NSAID and dual antithrombotic therapy without con-
current PPIs (5.2 (3.9 to 6.8) events per 100 person years) 
(hazard ratio 0.41, 0.20 to 0.84).
Different NSAID groups (selective COX 2 inhibitors, 
non-selective NSAIDs, other NSAIDs) and PPIs were 
associated with similar adjusted hazard ratios and 
crude incidence rates as for overall NSAID treatment 
(fig 3 , top). Individual PPIs (omeprazole, pantoprazole, 
lanzoprazole, and esmoprazole) were each associated 
with reduced bleeding risks (fig 3, bottom). For individ-
ual NSAIDs (rofecoxib, celecoxib, diclofenac, ibupro-
fen, naproxen), hazard ratios for bleeding were lower 
with concurrent PPI use than without, but not signifi-
cantly so owing to small numbers of events individually 
(supplementary table 4).
Sensitivity analyses
None of the sensitivity analyses changed the results 
appreciably (web appendix).
discussion
This nationwide study suggests that PPIs reduce the 
risk of gastrointestinal bleeding associated with NSAID 
use among post-myocardial infarction patients taking 
antithrombotics. Four PPIs (omeprazole, pantoprazole, 
lanzoprazole, esmoprazole) were individually associ-
ated with a lower risk of bleeding compared with non-
use for the antithrombotic regimens examined and 
irrespective of whether selective COX 2 inhibitors or 
non-selective NSAIDs were prescribed.
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Fig 2 | distribution of use of proton pump inhibitor (ppi), 
non-steroidal anti-inflammatory drug (nSaid), and both 
one year after myocardial infarction among patients taking 
single or dual antithrombotic treatment. left side y axis: 
curves represent percentages of entire cohort receiving ppi 
only, nSaid only, and both ppi and nSaid within one year 
from study inclusion after myocardial infarction. right side 
y axis: curve represents percentage receiving ppi (for at 
least one day) while on nSaid treatment within one year 
from study inclusion after myocardial infarction
Baseline characteristics of total study population and individual antithrombotic treatment groups. Values are numbers (percentages) unless stated 
otherwise
Characteristic
total population 
(n=82 955)
no ppi and no 
nSaid (n=68 044) nSaid (n=2006) ppi (n=12 334)
ppi and nSaid 
(n=571)
Mean (SD) age, years 67.4 (13.3) 66.7 (13.3) 67.7 (12.8) 71.4 (12.8) 68.7 (13.0)
Male sex 53 070 (64.0) 44 802 (65.8) 1199 (59.8) 6772 (54.9) 297 (52.0)
Comorbidities:
 Cardiac arrhythmias 7624 (9.2) 5821 (8.6) 164 (8.2) 1590 (12.9) 49 (8.6)
 Peripheral vascular disease 3132 (3.8) 2264 (3.3) 69 (3.4) 776 (6.3) 23 (4.0)
 Cerebral vascular disease 3716 (4.5) 2748 (4.0) 64 (3.2) 878 (7.1) 26 (4.6)
 Diabetes with complications 3404 (4.1) 2498 (3.7) 89 (4.4) 789 (6.4) 28 (4.9)
 Acute renal failure 628 (0.8) 339 (0.5) 10 (0.5) 268 (2.2) 11 (1.9)
 Chronic renal failure 1027 (1.2) 603 (0.9) 12 (0.6) 402 (3.3) 10 (1.8)
 Malignancy 1796 (2.2) 1296 (1.9) 35 (1.7) 442 (3.6) 23 (4.0)
 Shock 216 (0.3) 143 (0.2) 1 (0.1) 70 (0.6) 2 (0.4)
 Chronic obstructive pulmonary disease 690 (0.8) 522 (0.8) 12 (0.6) 148 (1.2) 8 (1.4)
 Previous bleeding 5511 (6.6) 3466 (5.1) 115 (5.7) 1826 (14.8) 66 (11.6)
 Liver disease 954 (1.2) 657 (1.0) 22 (1.1) 267 (2.2) 8 (1.4)
 Peptic ulcer 3481 (4.2) 1706 (2.5) 44 (2.2) 1671 (13.6) 60 (10.5)
 Alcohol 3255 (3.9) 2415 (3.6) 83 (4.1) 714 (5.8) 43 (7.5)
 Percutaneous coronary intervention 32 376 (39.0) 26 764 (39.3) 691 (34.5) 4725 (38.3) 196 (34.3)
Concomitant drugs:
 β blockers 60 789 (73.3) 50 541 (74.3) 1405 (70.0) 8446 (68.5) 394 (69.0)
 Angiotensin converting enzyme inhibitors 31 748 (38.3) 25 821 (38.0) 769 (38.3) 4928 (40.0) 230 (40.3)
 Statins 48 829 (58.9) 40 214 (59.1) 1156 (57.6) 7107 (57.6) 352 (61.7)
 Spironolactone 4771 (5.8) 3560 (5.2) 116 (5.8) 1048 (8.5) 47 (8.2)
 Loop diuretics 22 020 (26.5) 16 685 (24.5) 572 (28.5) 4563 (37.0) 200 (35.0)
 Glucose lowering drugs 6388 (7.7) 4860 (7.1) 195 (9.7) 1263 (10.2) 70 (12.3)
NSAID=non-steroidal anti-inflammatory drug; PPI=proton pump inhibitor.
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Adverse cardiovascular effects associated with 
NSAIDs have led to discouragement of their use in 
patients with cardiovascular disease.26 27 NSAIDs have 
also been associated with a substantial independent 
risk of bleeding in patients already taking antithrom-
botics.8 9 Nevertheless, they continue to be prescribed 
quite extensively for patients with cardiovascular risks. 
Previous studies have reported that around 40% of 
Danish patients with myocardial infarction are exposed 
to NSAIDs,13 14 22 consistent with the 42.5% found here. 
PPIs reduce the risks of gastrointestinal complications 
associated with antithrombotics and with NSAIDs, 
including among patients at high risk treated with 
selective or non-selective NSAIDs.28-32 Our results sup-
port these findings in showing that concurrent PPIs 
were associated with a reduced risk of gastrointestinal 
bleeding among post-myocardial infarction patients 
taking both NSAIDs and antithrombotics.
Concern has been expressed that some PPIs might 
diminish the antiplatelet effect of clopidogrel, most 
likely through inhibition of CYP2C19 mediated conver-
sion of clopidogrel into its active form, but studies have 
been contradictory and definitive data are awaited.33 
A similar situation exists regarding concerns that PPIs 
might impair the cardiovascular protective efficacy of 
aspirin.12  Consequently, PPIs are recommended for 
aspirin treated patients at high risk of gastrointestinal 
bleeding. American specialty guidelines recommend 
that in patients at high risk of gastrointestinal bleeding, 
a PPI should be used concomitantly with antithrombot-
ics and with NSAID treatment.15. Our data suggest that 
PPI treatment probably has a beneficial effect regard-
less of underlying gastrointestinal risk and that when 
NSAIDs cannot be avoided in post-myocardial infarc-
tion patients, physicians might prescribe a PPI as well. 
Our study does not clarify whether PPIs might be safely 
omitted in specific subgroups of patients with a low risk 
of gastrointestinal bleeding.
limitations of study
The main limitation of this study is its observational 
non-randomised design. Furthermore, we do not have 
information on whether patients stop taking anti-
thrombotics when treated with NSAIDs; however, given 
post-myocardial infarction treatment guidelines, we 
think that this is unlikely. We cannot exclude a possible 
effect of unmeasured confounders. However, if an 
unmeasured confounder or a combination of con-
founders were present in 20% of the NSAID treated 
cohort, our calculations suggest that the confounder 
would have to increase the risk by a factor of 1.8 to 3.5 
to explain the increased risk observed. Existence of 
such a confounder or combination of confounders is 
unlikely, but not impossible, as we had no information 
on other risk factors such as smoking, lipid concentra-
tions, or body mass index. Moreover, we did an analy-
sis with continuous assessment of co-variables to 
account for accumulation of risk factors during fol-
low-up to further minimise the effect of potential con-
founders; the results were unaffected. We did not have 
information about the indication for NSAID treatment, 
but this was probably for non-cardiac disease, as 
NSAIDs are not used to treat ischaemic heart disease. 
Having users treated with the drug(s) under investiga-
tion before inclusion could result in confounding 
(healthy user effect). Our estimates when we excluded 
prevalent NSAID users remained the same, so it is 
unlikely that confounding by indication alone could 
drive the observed results. The only NSAID available 
over the counter in Denmark is ibuprofen (since 2001) 
in low doses (200 mg) and in limited quantity. Restrict-
ing the analyses to 1997-2000 did not change our 
results. Aspirin is also available without prescription, 
but because of partial reimbursement of drug expenses, 
chronic users, in particular those with a history of myo-
cardial infarction, are most likely to be issued with a 
prescription for aspirin as thrombo-prophylaxis.34 35 
For these reasons, we think unrecorded over the 
counter drug use is unlikely to have had a major effect 
on the study results. Several estimates of a beneficial 
effect of concomitant specific PPI and specific NSAID 
treatment on risk of gastrointestinal bleeding were 
non-significant. This was potentially owing to a low 
number of events. Nevertheless, all estimates were 
comparable to our main analysis.
Conclusion
This study of a real life cohort of post-myocardial infarc-
tion patients taking antithrombotics suggests that use 
of a PPI diminishes the risk of gastrointestinal bleeding 
associated with NSAID treatment, regardless of the type 
of NSAID or PPI prescribed. Consequently, when 
NSAIDs cannot be avoided in post-myocardial infarc-
tion patients, physicians might consider prescribing a 
PPI as well.
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Fig 3 | Cox proportional hazard analysis risk of gastrointestinal bleeding on antithrombotic 
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